Global Gastroretentive Drug Delivery System Market is Segmented By Type(Floating drug delivery system, Bioadhesive drug delivery system
, Other), By Dosage Form (Tablets, Capsule, Microspheres, Liquid, Others), By Distribution Channel (Online pharmacies, Retail Pharmacies, Hospital pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Market Overview
The "Global Gastroretentive Drug Delivery System Market" is predicted to reach at a high CAGR of 6.4% during the forecast period (2023-2030).
Gastroretentive drug delivery system is novel drug delivery system that has an upper hand owing to its ability of prolonged retaining ability in the stomach and thereby increase the gastric residence time of drugs and also improves the bioavailability of drugs.
They have curative efficiency and an increase in the bioavailability of drugs. And are effective in treating duodenal and gastric ulcers, including esophagitis, by eliminating deeply buried helicobacter pylori from the submucosal tissue of the stomach. Gastroretentive dosage forms are one of the oral site-specific drug delivery systems that have been proposed.
Source: DataM Intelligence Analysis (2020)
Market Dynamics
Gastroretentive drug delivery system market is driven by an increase in a number of various disorders related to the small intestine and stomach. The curative efficiency and an increase in the bioavailability of drugs. Floating drug delivery systems require a high fluid level in the stomach to float and work effectively.
An increase in number of various disorders related to the small intestine and stomach will drive the market growth
Gastroretentive drug delivery system sustains the release of drugs and avails local Dosage Form in the small intestine and stomach. Rising cases of stomach and small-intestine-related disorders are anticipated to increase the demand in the market.
According to a new national survey of more than 2,000 U.S. adults, 72 percent said they had experienced at least one of the following gastrointestinal (GI) symptoms a few times a month or more: diarrhoea, gas, bloating, stomach pain, frequent bowel movements, unexplained weight-loss and non-specific GI discomfort.
The curative efficiency and an increase in bioavailability of drugs
The drug delivery system of gastroretentive dosage form has evolved. It has the upper hand owing to its ability of prolonged retaining ability in the stomach. This improves the gastric residence span of drugs in the stomach. This elongated retention ability provides more benefits which may be enumerated as improving activity span for short half-life drugs, the bioavailability of drugs, exclusion of side effects, reduction in dosage periodicity, saving drugs owing to former benefit, improves solubility for drugs that are less soluble in a high pH environment, optimized Dosage Form and ultimately easy compliance on the part of the patient.
Floating drug delivery systems require a high fluid level in the stomach to float and work effectively
To increase the gastric residence time of drug delivery systems include bioadhesive systems, floating systems (low-density systems), non-floating systems (high-density systems), magnetic systems, swelling systems, unfoldable and expandable systems, raft forming systems and super porous systems, biodegradable hydrogel systems. In this, the major disadvantage of a floating system is the necessity of a sufficient level of gastric fluids to float without a sink. However, this limitation can be overcome by coating the dosage form with bio adhesive polymers that easily adhere to the gastric mucosa.
COVID-19 Impact Analysis
The gastroretentive drug delivery system market experienced a mild impact due to the ongoing COVID-19 pandemic in some regions due to the production restrictions. However, due to growing demand, online prescription and e-pharmacy services, the impact reduced with growing demand.
Segment Analysis
By type, the gastroretentive drug delivery system is divided into the high-density system, floating drug delivery system, bioadhesive drug delivery system, expandable drug delivery system, and others.
Floating drug delivery system held the largest share
Floating drug delivery systems (FDDS) are invented to retain the drug in the stomach and applicable for drugs with poor solubility and low stability in intestinal fluids. The basis behind FDDS is making the dosage form less dense than the gastric fluids to make it float on them. It has increased gastric retention time and offers improved control over fluctuation in plasma drug concentration, which is one reason for its growth in the market.
Based on Dosage Form, the market is segmented into capsule, microspheres, liquid, tablets, and others.
The tablet segment dominated the market
The increasing focus of manufacturers on developing gastroretentive tablets is expected to maintain a strong position in the market. The density of tablets is lower than the density of stomach fluid, causing buoyancy in gastric fluid, making it preferable among patients.
Source: DataM Intelligence Analysis (2020)
By Distribution Channel, the gastroretentive drug delivery system market is classified into online pharmacies, retail pharmacies, and hospital pharmacies.
Online pharmacies will see growth over the forecast period
The growth is accredited to convenience and user-friendly interfaces offered by online pharmacies in terms of prices, delivery and access. Along with discounts they offer online.
With the impact of COVID-19, people have switched mostly to e-commerce shopping for safe and better purchases.
Geographical Analysis
North America held dominated the gastroretentive drug delivery system market
The high prevalence of gastric cancer, increasing R&D expenditure, and rising initiatives by market participants in developing advanced gastroretentive drug delivery systems in the U.S. and Canada contributed considerably to North America’s leading market share. Better adoption of healthcare and follow-up of advanced treatment methods. The increasing occurrence of gastric disorders in the region is anticipated to increase its market.
Competitive Landscape
An increase in product quality, clinical research and innovations are major strategies adopted by the key players to retain their market share. Some of the key players in this market are Pharmacia, Galenix, Depomed, Ranbaxy, Sun Pharma, Pfizer, Lupin, Glaxo Smith Kline, F.Hoffmann La Roch and Alcon, Inc.
Galenix
Overview: GALENIX was founded in 1993 by its CEO, M. JĂ©rĂ´me BESSE. The company is now ranked in the top European leaders for Pharmaceutical R&D and Drug Delivery Systems.
GALENIX is an ideal strategic partner for outsourcing pharmaceutical development and innovative drug product acquisitions, with a full range of services for each stage of the pharmaceutical development process from preformulation, analytical development and validation, formulation, scale-up, quality control, ICH stability studies to the registration of drug products. Galenix property Drug Delivery Systems are all based on simple manufacturing processes and conventional excipients listed in EU and US Pharmacopeias.
Minimum Excipient Tablet and gastroretentive effect
MINEXTAB® Floating is a valuable tool for active ingredients with a narrow absorption window.
This gastro-retentive delivery system (GRDDS) has is based on MINEXTAB® technology, with floating and swelling features to prolong the gastric retention time.
Product Portfolio: The company’s portfolio comprises outsourcing pharmaceutical development, innovative drug product acquisitions and a full range of services for the pharmaceutical development process from preformulation analytical development, validation, formulation, scale-up, quality control, ICH stability studies to the registration of drug products.
Why Purchase the Report?
- Visualize the composition of the Gastroretentive Drug Delivery System Market segmentation by type, Dosage Form and Distribution Channel the key commercial assets and players.
- Identify commercial opportunities in Gastroretentive Drug Delivery System Market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of Gastroretentive Drug Delivery System Market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The Gastroretentive Drug Delivery System Market report would provide an access to an approx. 61 market data table, 54 figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
